Intestinal Lavage for the Treatment of Severe C. Difficile Infections
NCT02466698 · Status: UNKNOWN · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 20
Last updated 2018-08-13
Summary
Clostridium Difficile infections (CDIs) are treated initially with antibiotic therapy and supportive care, with surgical intervention reserved for patients with significant systemic toxicity or perforation. Severe CDI may be refractory to medical management and require surgical intervention, carrying a mortality of approximately 40%.
Mortality associated with CDI increases significantly as the severity of the infection increases. In patients failing medical management, earlier operation is associated with decreased mortality. However, the lack of validated tools to predict the necessity for surgical intervention, combined with the significant morbidity associated with total colectomy significantly reduces the likelihood of patients receiving early surgical intervention. The purpose of the proposed study is to assess the addition of intestinal PEG lavage via nasojejunal tube to usual care in the treatment of adult patients with severe CDI who have no immediate indication for surgical intervention.
Conditions
- Clostridium Difficile
Interventions
- PROCEDURE
-
Intestinal Lavage
A nasojejunal tube and fecal management system will be inserted. Intestinal lavage with PEG is initiated and increased to a goal rate of 400cc/hour to a total of 8L of PEG. In the absence of an ileus, lavage should be initiated at 200cc/hr. Tolerance is confirmed if the rectal effluent volume is ≥50% of the lavage volume over the first 6 hours and no emesis has developed. If the consulting surgical service suspects a significant ileus, the lavage is initiated at 100cc/hr. If tolerance is confirmed the lavage rate is increased in a stepwise fashion. Antibiotic regimen will consist of Vancomycin 500mg via nasojejunal every 6 hours and Metronidazole 500 mg IV three times daily for 14 days. PEG will be held for 2 hours after administration of Vancomycin.
- DRUG
-
Patients will receive standard antibiotic treatment for severe CDI. This includes an antibiotic regimen of Vancomycin 500mg orally every 6 hours and Metronidazole 500mg IV three times daily for 14 days. The standard medical care group (active comparator group) will receive the same antibiotic doses as the experimental arm of the study For both arms, indications to escalate treatment to surgical intervention will ultimately be based on the clinical assessment by the surgical service. An absolute indication for surgery is perforation. Other indications such as toxic megacolon, worsening peritonitis or biochemical profile lavage are relative indications that vary according to clinician and individual patient characteristics.
- DRUG
-
PEG
Polyethylene glycol 3350, 8L in 48 hours, via a nasojejunal tube will be used to facilitate intestinal lavage.
- DRUG
-
Metronidazole
Patients will receive standard antibiotic treatment for severe CDI. This includes an antibiotic regimen of Vancomycin 500mg orally every 6 hours and Metronidazole 500mg IV three times daily for 14 days. The standard medical care group (active comparator group) will receive the same antibiotic doses as the experimental arm of the study For both arms, indications to escalate treatment to surgical intervention will ultimately be based on the clinical assessment by the surgical service. An absolute indication for surgery is perforation. Other indications such as toxic megacolon, worsening peritonitis or biochemical profile lavage are relative indications that vary according to clinician and individual patient characteristics.
Sponsors & Collaborators
-
London Health Sciences Centre
collaborator OTHER -
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
lead OTHER
Principal Investigators
-
Tina E Mele, MD PhD · London Health Sciences Centre
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- SINGLE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2016-08-31
- Primary Completion
- 2019-08-31
- Completion
- 2019-08-31
Countries
- Canada
Study Locations
More Related Trials
-
FMT for Moderate to Severe CDI: A Randomised Study With Concurrent Stool Microbiota Assessment
NCT02570477 ·Status: UNKNOWN ·Phase: NA
-
Protocol for Admission Toxigenic C. Difficile Surveillance
NCT04014608 ·Status: COMPLETED
-
Fecal Filtrate as a Treatment Option of Multiple Recurrent Clostridioides Difficile Infection
NCT04960306 ·Status: NOT_YET_RECRUITING ·Phase: PHASE3
-
Response of Clostridium Difficile Infection to Metronidazole Therapy
NCT00304369 ·Status: COMPLETED
-
Clostridioides Difficile Colonisation
NCT05693077 ·Status: RECRUITING ·Phase: PHASE1
-
Harnessing the Healthy Gut Microbiota to Cure Patients With Recurrent C. Difficile Infection
NCT01372943 ·Status: TERMINATED ·Phase: NA
-
Prospective Trial of Oral Vancomycin Therapy vs. Placebo for Prevention of CDI
NCT04241744 ·Status: WITHDRAWN ·Phase: PHASE4
-
Fecal Microbiota Transplantation for Severe Clostridium Difficile Infection
NCT03427229 ·Status: COMPLETED ·Phase: PHASE2
-
Initial Vancomycin Taper for the Prevention of Recurrent Clostridium Difficile Infection
NCT04138706 ·Status: COMPLETED ·Phase: PHASE3
-
Does Fidaxomicin Therapy Reduce Spread of Clostridium Difficile?
NCT02461901 ·Status: COMPLETED
-
Addition of Lactobacillus to Metronidazole in Treatment of CDAD
NCT00304863 ·Status: WITHDRAWN ·Phase: PHASE4
-
A Study of GT267-004 Versus Vancomycin and GT267-004 Versus Metronidazole in Patients With C.Difficile - Associated Diarrhea
NCT00106509 ·Status: COMPLETED ·Phase: PHASE3
-
Clostridial Infection and Oral Lavage -Improving Treatment Before Illness Becomes Severe
NCT01630096 ·Status: UNKNOWN ·Phase: PHASE4
-
Small Bowel Transit Time in Clostridium Difficile Colitis
NCT01309750 ·Status: TERMINATED
-
Vancomycin Taper to Prevent Recurrent Clostridioides Difficile
NCT07328971 ·Status: RECRUITING ·Phase: PHASE3
-
STOP-CDI: Efficacy of Fecal Microbiota Transplantation vs Fidaxomicin vs Vancomycin in Treating and Preventing Relapse of Clostridioides Difficile Infection
NCT07120490 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
IMT for Primary Clostridium Difficile Infection
NCT02301000 ·Status: TERMINATED ·Phase: PHASE2/PHASE3
-
Impact of Oral Antibiotic Treatment on C. Difficile
NCT02057198 ·Status: COMPLETED ·Phase: PHASE4
-
Oral Vancomycin Versus Probiotics Versus Placebo for Prevention of Clostridium Difficile Infection in Colonized Patients
NCT04246151 ·Status: WITHDRAWN ·Phase: EARLY_PHASE1
-
Reduction of C-Difficile Infection Using Stool Transplant
NCT02112279 ·Status: UNKNOWN ·Phase: PHASE1
-
Fecal Transplant for Pediatric Patients Who Have Recurrent C-diff Infection
NCT02134392 ·Status: UNKNOWN ·Phase: PHASE1
-
Fecal Microbiota Therapy for Recurrent Clostridium Difficile Infection
NCT02686645 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3
-
Host Immune Response to Clostridium Difficile Infection (ICD)
NCT02440438 ·Status: COMPLETED ·Phase: NA
-
Efficacy of Metronidazole Prophylaxis Against Clostridium Difficile-Associated Diarrhea in High Risk Adult Patients
NCT02200328 ·Status: TERMINATED ·Phase: PHASE4
-
Fecal Microbiota Transplantation for Primary Clostridium Difficile Diarrhea
NCT02801656 ·Status: WITHDRAWN ·Phase: PHASE3